Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines.

Breast · 2026 · PMC12719210 · PMID 41338056

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

4 Discussion In this population-based study, a decreasing trend in ET use was observed among HR+/HER2- breast cancer patients for whom treatment with ET was recommended according to national guidelines.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.